DESTINY-Breast07: Efficacy (Results from Part 2/Modules 0 [T-DXd monotherapy] and 2 [T-DXd + pertuzumab] as of December 22, 2023 DCO)
Response to treatment per RECIST v1.1 by investigator (Part 2/Module 0 & 2)1
Response to treatment per RECIST v1.1 by investigator (Part 2/Module 0 & 2)1
Response to treatment per RECIST v1.1 by investigator (Part 2/Module 0 & 2)1
Dashed reference line at −30% indicates the threshold for partial response. Responses are captured for patients with baseline data and at least one follow-up assessment
Median duration of follow up was 23.9 months for T-DXd monotherapy and 25.3 months for T-DXd + pertuzumab
*Patients had 0% change from baseline.
Percentage change in target lesion size from baseline1
Percentage change in target lesion size from baseline1
Percentage change in target lesion size from baseline1
Dashed reference line at −30% indicates the threshold for partial response
Median duration of follow up was 23.9 months for T-DXd monotherapy and 25.3 months for T-DXd + pertuzumab
Duration of response1
Duration of response1
Duration of response1
Median duration of follow up was 23.9 months for T-DXd monotherapy and 25.3 months for T-DXd + pertuzumab
Progression-free survival1
Progression-free survival1
Progression-free survival1
The number of PFS events is small and most patients were censored
Median duration of follow up was 23.9 months for T-DXd monotherapy and 25.3 months for T-DXd + pertuzumab
Confirmed ORR and BOR by subgroup per RECIST v1.1 by investigator1
Confirmed ORR and BOR by subgroup per RECIST v1.1 by investigator1
Confirmed ORR and BOR by subgroup per RECIST v1.1 by investigator1
Progression-free survival by subgroup1
Progression-free survival by subgroup
Progression-free survival by subgroup
The number of PFS events is small and diverse most patients were censored
Abbreviations
BOR = best observed response
;cORR = confirmed objective response rate
;CR = complete response
;DCO = data cut-off
;DOR = duration of response
;HER2 = human epidermal growth factor receptor 2
;HR = hormone receptor
;NE = not estimable
;mBC = metastatic breast cancer
;ORR = objective response rate
;PR = partial response
;RECIST = Response Evaluation Criteria in Solid Tumors
;SD = stable disease
;T-DXd = trastuzumab deruxtecan
References
1. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
To help us improve our content for health care professionals, please take this short survey.
Document ID: 325e86bc-2a1f-401a-b8d6-fa304896a85b
Last updated: 14-February-2023
©2023 AstraZeneca. All rights reserved.